CVKD · Cadrenal Therapeutics, Inc.
$2.05
+0.02 (+0.99%)
At close · Jul 24
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern for at least one year following the issuance of the accompanying financial statements.”View the 10-Q filed May 7, 2026
Market Cap
$5.85M
Shares
2.87M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$13.24M
-24.3%
FY2025
Diluted EPS
-$6.64
+23.9%
FY2025
Operating Cash Flow
-$12.6M
-71.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | — | — | $220.1K | $220.1K | |
| $771.51K | $4.1M | $4.21M | $4.08M | $200K | |
| $8.84M | $9.35M | $6.75M | $3.55M | $2.31M | |
| $12.05M | $13.46M | $10.96M | $7.63M | $2.7M | |
| -$12.05M | -$13.46M | -$10.96M | -$7.63M | -$2.7M | |
| — | — | — | $3534 | $40.19K | |
| $159.06K | $223.82K | $309.25K | -$724.24K | — | |
| -$11.89M | -$13.24M | -$10.65M | -$8.36M | -$6.71M | |
| -$11.89M | -$13.24M | -$10.65M | -$8.36M | — | |
| USD/shares | — | -$6.64 | -$8.73 | -$9.29 | -$12.75 |
| USD/shares | — | -$6.64 | -$8.73 | -$9.29 | -$12.75 |
| shares | — | 1.99M | 1.22M | 899.47K | 526.03K |
| shares | — | 1.99M | 1.22M | 899.47K | 526.03K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×